{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:36:50Z","timestamp":1784932610352,"version":"3.55.0"},"reference-count":58,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T00:00:00Z","timestamp":1410739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Obesity is a major correlate of cardiovascular disease. Weight loss improves cardiovascular risk factors and has the potential to improve outcomes. Two drugs, phentermine plus topiramate and lorcaserin, have recently been approved by the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> Food and Drug Administration for the indication of obesity; a third, bupropion plus naltrexone, is under consideration for approval. In clinical trials, these drugs cause weight loss and improve glucose tolerance, lipid profile, and, with the exception of bupropion plus naltrexone, blood pressure. However, their effect on cardiovascular outcomes is unknown. In defining appropriate roles for these drugs in preventive cardiology, it is important to remember the checkered history of drugs for obesity. New weight\u2010loss drugs share the serotonergic and sympathomimetic mechanisms that proved harmful in the cases of Fen\u2010Phen and sibutramine, respectively, albeit with significant differences. Given these risks, randomized cardiovascular outcomes trials are needed to establish the safety, and potential benefit, of these drugs. This review will discuss the history of pharmacotherapy for obesity, existing efficacy and safety data for the novel weight\u2010loss drugs, and issues in the design of postapproval clinical trials.<\/jats:p>","DOI":"10.1002\/clc.22304","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T16:42:30Z","timestamp":1410799350000},"page":"693-699","source":"Crossref","is-referenced-by-count":35,"title":["Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit"],"prefix":"10.1002","volume":"37","author":[{"given":"Jonathan W.","family":"Cunningham","sequence":"first","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Wiviott","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa053935"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.732"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.90"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281361"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.300655"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2007.03.006"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432501"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.69"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391103"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901"},{"issue":"24","key":"e_1_2_8_14_1","article-title":"The $22 billion gold rush","author":"Lenzner R","year":"2006","journal-title":"Forbes March"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.7.761"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.028381"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60935-X"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"e_1_2_8_20_1","unstructured":"ColmanE.Slides presented at: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee: Adelphi MD; September 15 2010."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60318-4"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066254"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.155"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401329"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.135178"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.5835"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc0502.103331"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2023"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212914"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1256"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.66"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909809"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0234"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-12-41"},{"key":"e_1_2_8_41_1","unstructured":"DiesF KrellM WhitlowP. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure (abstract).Circulation. 1986;74(suppl II):S38."},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318235eb4d"},{"key":"e_1_2_8_43_1","unstructured":"USFoodandDrug Administration. Clinical briefing document QNEXA (phentermine\/topiramate). Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Silver Spring MD; February 22 2012."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001298"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072327"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133348"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.10.008"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068265"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm764"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.112.000128"},{"key":"e_1_2_8_51_1","unstructured":"USFoodandDrug Administration FDA briefing document lorcaserin hydrochloride tablets 10\u2009mg. Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Silver Spring MD; May 10 2012."},{"key":"e_1_2_8_52_1","unstructured":"USFoodandDrug Administration Addendum to the FDA briefing document. Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Silver Spring MD; May 10 2012."},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)01064-9"},{"key":"e_1_2_8_54_1","unstructured":"USFoodandDrug Administration. FDA briefing document Contrave. Presented at: Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Silver Spring MD; December 7 2010."},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"e_1_2_8_56_1","volume-title":"Guidance for Industry, Diabetes Mellitus\u2014Evaluating Cardiovscular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","author":"Food US","year":"2008"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.9931"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1211277"},{"key":"e_1_2_8_59_1","unstructured":"European Medicines Agency. Concept paper on the need for revision of the guidelines of medical products used in weight control.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/10\/WC500133166.pdf. Published Septem-ber 20 2012."}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22304","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:46:57Z","timestamp":1696326417000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,15]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1002\/clc.22304"],"URL":"https:\/\/doi.org\/10.1002\/clc.22304","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,15]]}}}